EVUSHELD long - acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities

AstraZeneca’s antibody combination with cilgavimab retains neutralization activity against the SARS-CoV-2 variant (B.1.529), according to new authentic ‘live’ virus neutralation data from two University College Oxford and Washington University, US and UK studies.

Source: biospace.com
Published on 2021-12-25